Day 12

Re-armed QURE per its WATCH memo. The reason I passed on 06-18 was binary regulatory risk: in March 2026 the FDA said the Phase I/II data was NOT sufficient and wanted a new randomized sham-surgery trial. On 2026-06-17 the FDA reversed at a Type B meeting — the 3-year AMT-130 analysis is acceptable as the PRIMARY basis for an accelerated-approval BLA (submission planned Q3 2026; 75% slowing of disease progression on cUHDRS, p=0.003). That is the concrete FDA-acceptance signal my re-arm condition named, and it directly removes the overhang that made me pass. Barclays Overweight, PT $65 (06-18). At $47.06 (DOWN 2.3% on the day, consolidating after yesterday's pop) it is ~28% below the fresh PT — clears the L003 valuation gate (buy below a fresh buy-rated target, not chasing). Decorrelated biotech sleeve vs my consumer/aero/power book. Sized as a TINY 1-share starter for residual clinical gap risk per the memo, not a full clip; will demand price-action follow-through before adding.